799 results on '"Crinò, Lucio"'
Search Results
102. Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)
103. Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients
104. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
105. Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
106. Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
107. Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
108. Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
109. Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
110. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement
111. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
112. MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies
113. The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial
114. Epidermal Growth Factor Receptor Exon 19 Deletions Predict Complete Regression of Multiple Intracranial Metastases in Two Cases of Non-small Cell Lung Cancer Treated with Erlotinib
115. Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation
116. Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
117. Challenging Problems in Malignancy: CASE 1. Presentation of Small-Cell Lung Cancer With Marked Hyperamylasemia
118. Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non–Small-Cell Lung Cancer
119. MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) AND AKT AS PREDICTIVE FACTORS FOR RESPONSE TO ZD 1839 THERAPY IN NON- SMALL CELL LUNG CANCER (NSCLC) PATIENTS
120. A PARALLEL RANDOMIZED PHASE II TRIAL EVALUATING STANDARD VERSUS PROLONGED INFUSION GEMCITABINE (G) AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
121. Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer
122. Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
123. Kit Expression in Small Cell Carcinomas of the Lung: Effects of Chemotherapy
124. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
125. Targeted therapy in combination with gemcitabine in non-small cell lung cancer
126. Supplemental_Information – Supplemental material for Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
127. Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools
128. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
129. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer
130. New generation anaplastic lymphoma kinase inhibitors
131. Molecular targeted therapies in non-small cell lung cancer: where we are
132. Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
133. Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
134. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
135. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population
136. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
137. The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
138. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
139. Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
140. Present and future treatment of advanced non–small cell lung cancer
141. Gemzar platinum combinations: phase III trials in non-small cell lung cancer
142. Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer
143. CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study
144. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non–Small-Cell Lung Cancer
145. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
146. A step forward in the management of a rare disease, the anaplastic lymphoma kinase-rearranged non-small cell lung cancer
147. Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR)
148. Abstract 2254: Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools
149. Epithelial‐to‐mesenchymal transition in the context of epidermal growth factor receptor inhibition in non‐small‐cell lung cancer
150. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.